Update on bb2121, Potential Advanced Multiple Myeloma Therapy, Set for ASCO 2018 – Myeloma Research News
Myeloma Research News |
Update on bb2121, Potential Advanced Multiple Myeloma Therapy, Set for ASCO 2018
Myeloma Research News Celgene's investigational and second-generation CAR T-cell therapy bb2121 is showing real promise in treating advanced multiple myeloma patients, those with relapsed or refractory disease, updated Phase 1 data is expected to show. An earlier analsyis … |
